Respiratory viral infections continue to impose a large burden of hospitalization, organ failure and death, particularly among older adults and people with cardiometabolic disease. Whether prior semaglutide exposure is associated with lower post-infection severity across distinct respiratory viruses remains uncertain. We analyzed de-identified longitudinal electronic health record data from a federated U.S. network spanning more than 29 million patients. Adults with documented COVID-19 or influenza infection were classified by pre-infection semaglutide use versus no prior GLP-1 receptor agonist use and one-to-one propensity matched on demographics, BMI, HbA1c, vaccination status, prior infection status, antiviral use, healthcare utilization extent, several comorbidities, yielding matched cohorts of N=11,238 for COVID-19 and N=3,409 for influenza (flu). In the COVID-19 cohort, semaglutide exposure was associated with significantly lower (all P<0.001) 30-day mortality (0.1% vs 0.4%, RR 0.26), hospitalization (4.2% vs 7.2%, RR 0.58), ICU admission (1.0% vs 1.9%, RR 0.52), mechanical ventilation (0.4% vs 0.8%, RR 0.49), and the composite of all the outcomes listed (4.4% vs 7.7%, RR 0.57). In the flu cohort, semaglutide use was also associated (all P≤0.03) with significantly lower hospitalization (4.4% vs 7.8%, RR 0.57), ICU admissions (1.3% vs 1.9%, RR 0.67), mechanical ventilation (0.3% vs 0.6%, RR 0.43), and the composite outcome (4.5% vs 8.1%, RR 0.56). Significant risk reductions (all P<0.005) were also observed for acute coronary syndrome (COVID-19 RR 0.55; flu RR 0.42), acute respiratory failure (COVID-19 RR 0.63; flu RR 0.45), and acute kidney injury (COVID-19 RR 0.56; flu RR 0.54) in the 30-day observation period. Within the COVID-19 cohort, across both the full study period (vaccinated: RR, 0.54; unvaccinated: RR, 0.58) and specifically during the pandemic period ending May 11, 2023 (vaccinated: RR, 0.63; unvaccinated: RR, 0.59), prior semaglutide exposure was associated with significantly (p<0.01) and comparably lower composite COVID-19 severity, suggesting a public-health signal that may complement vaccination in documented recently vaccinated patients while also identifying a potentially scalable risk-reduction strategy for patients without documented recent vaccination. When restricting to those treated with standard-of-care therapeutics during the COVID-19 pandemic era, semaglutide users had significantly lower (p<0.05) 30-day composite risk among those on metformin (4.8% vs 7.6%; RR 0.64) and among those receiving Paxlovid ±7 days of infection (3.6% vs 10.1%; RR 0.35). Among those initiating corticosteroids ±7 days of infection, mortality and ICU admission were numerically lower but not statistically significant. Among the influenza cohort, semaglutide-associated composite risk reduction was comparable across vaccination strata (unvaccinated: RR, 0.56; vaccinated: RR, 0.59), suggesting a complementary public-health signal for reducing seasonal influenza severity both after documented vaccination and among patients without documented recent flu vaccination. Notably, semaglutide significantly reduced (P<0.01) composite risk even among adults aged ≥65 years for both COVID-19 (7.9% vs 11.8%; RR 0.67) and influenza (11.8% vs 16.2%; RR 0.73). Finally, composite risk did not vary significantly across pre-infection weight loss strata of <5%, 5–15%, and ≥15% for COVID (P=0.89) or flu (P=0.54), or across dosage strata of 0.25–0.5, 1.0, and 1.7–2.4 mg/week for COVID (P=0.50) or flu (P=0.32), suggesting semaglutide associated COVID and Flu protection may not require substantial weight loss or maximal dosing. Taken together with growing evidence of weight-loss-independent benefits of cardiovascular, renal, pulmonary and neurological systems, this study motivates prospective evaluation of low-dose semaglutide to blunt the severity of respiratory viral infections.